欧林生物
(688319)
| 流通市值：46.58亿 | | | 总市值：46.64亿 |
| 流通股本：4.05亿 | | | 总股本：4.06亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 386,646,898.48 | 226,277,670.03 | 70,798,700.81 | 496,118,667.03 |
| 营业收入 | 386,646,898.48 | 226,277,670.03 | 70,798,700.81 | 496,118,667.03 |
| 二、营业总成本 | 379,815,023.64 | 244,503,957.28 | 109,128,006.76 | 490,851,002.62 |
| 营业成本 | 20,425,109.52 | 12,303,240.64 | 5,356,618.81 | 31,998,151.23 |
| 税金及附加 | 2,226,976.66 | 1,599,701.24 | 402,426.72 | 3,322,399.25 |
| 销售费用 | 185,241,304.11 | 102,821,367.26 | 23,923,785.82 | 257,806,065.58 |
| 管理费用 | 63,044,731.6 | 46,873,708.04 | 29,430,197.27 | 78,313,262.91 |
| 研发费用 | 99,399,717.64 | 75,288,312.43 | 47,738,722.74 | 114,729,216.26 |
| 财务费用 | 9,477,184.11 | 5,617,627.67 | 2,276,255.4 | 4,681,907.39 |
| 其中:利息费用 | 10,383,811.72 | 6,374,239.33 | 2,790,891.37 | 7,178,400.62 |
| 其中:利息收入 | 1,101,681.82 | 902,987.64 | 514,635.97 | 2,553,649.43 |
| 加:投资收益 | 500,625.69 | 178,893.35 | 18,657.53 | 1,041,729.01 |
| 资产处置收益 | - | - | - | -149,543.14 |
| 资产减值损失(新) | 5,074,024.15 | 5,410,956.23 | 6,232,979.5 | -4,727,853.13 |
| 信用减值损失(新) | -15,589,377.17 | -21,914,696.83 | 2,638,065.18 | -1,586,881.84 |
| 其他收益 | 3,702,801 | 2,807,191.33 | 1,129,014.07 | 3,253,294.04 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 519,948.51 | -31,743,943.17 | -28,310,589.67 | 3,098,409.35 |
| 加:营业外收入 | 1,044,193.66 | 1,041,527.85 | 1,039,197.9 | 12,550,174.2 |
| 减:营业外支出 | 116,871.33 | 16,756.05 | 24,438.05 | 32,121.74 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 1,447,270.84 | -30,719,171.37 | -27,295,829.82 | 15,616,461.81 |
| 减:所得税费用 | 1,530,181.21 | - | - | 4,175,335.12 |
| 六、净利润 | -82,910.37 | -30,719,171.37 | -27,295,829.82 | 11,441,126.69 |
| 持续经营净利润 | -82,910.37 | -30,719,171.37 | -27,295,829.82 | 11,441,126.69 |
| 归属于母公司股东的净利润 | 4,025,906.59 | -27,947,000.01 | -25,996,930.16 | 17,555,561.77 |
| 少数股东损益 | -4,108,816.96 | -2,772,171.36 | -1,298,899.66 | -6,114,435.08 |
| (一)基本每股收益 | 0.01 | -0.07 | -0.06 | 0.04 |
| (二)稀释每股收益 | 0.01 | -0.07 | -0.06 | 0.04 |
| 九、综合收益总额 | -82,910.37 | -30,719,171.37 | -27,295,829.82 | 11,441,126.69 |
| 归属于母公司股东的综合收益总额 | 4,025,906.59 | -27,947,000.01 | -25,996,930.16 | 17,555,561.77 |
| 归属于少数股东的综合收益总额 | -4,108,816.96 | -2,772,171.36 | -1,298,899.66 | -6,114,435.08 |
| 公告日期 | 2024-10-30 | 2024-08-22 | 2024-04-26 | 2024-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |